PanTarg develops antibody-drug conjugates for pancreatic cancer and other solid tumors.
pantarg has raised $1.5M in total funding. The most recent round was Pre-Seed. The last funding was announced in September 2026.
pantarg's investors include BioInnovation Institute Venture Lab.
pantarg is headquartered in Copenhagen, Denmark.
PanTarg develops antibody-drug conjugates for pancreatic cancer and other solid tumors.
pantarg is at the Pre-Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"pantarg — Funding & Investors." VCBacked, September 8, 2026, https://www.vcbacked.co/company/pantarg. Accessed September 30, 2026.
VCBacked. (2026). pantarg — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/pantarg
{{cite web |title=pantarg — Funding & Investors |url=https://www.vcbacked.co/company/pantarg |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated